Abstract
The primary goal of psychosomatic medicine is the incorporation of its operational strategies into clinical practice. The traditional attitude toward disease and the functional/organic dichotomy were criticized by George Engel in the early sixties. Only recently, however, there has been increasing awareness of the limitations of disease as the primary focus of medical care. It is not that certain disorders lack an organic explanation; it is our assessment that is inadequate in most clinical encounters. The research evidence which has accumulated in psychosomatic medicine offers unprecedented opportunities for the identification and treatment of medical problems. Taking full advantage of clinimetric methods (such as the use of Emmelkamp’s two levels of functional analysis and the Diagnostic Criteria for Psychosomatic Research) may greatly improve the clinical process, including shared decision making and self-management. Endorsement of the psychosomatic perspective may better clarify the pathophysiological links and mechanisms underlying symptom presentation. Pointing to individually targeted methods may improve final outcomes and quality of life.
References
1.
Engel GL: A unified concept of health and disease. Perspect Biol Med 1960;3:459–485.
2.
Engel GL: Is grief a disease? A challenge for medical research. Psychosom Med 1961;23:18–22.
3.
Maj M: Are we able to differentiate between true mental disorders and homeostatic reactions to life events? Psychother Psychosom 2007;76:257–259.
4.
Buchi S, Mörgeli H, Schnyder U, Jenewein J, Hepp U, Jina E, Neuhaus R, Fauchère JC, Bucher HU, Sensky T: Grief and post-traumatic growth in parents 2–6 years after the death of their extremely premature baby. Psychother Psychosom 2007;76:106–114.
5.
Engel GL: The need for a new medical model: a challenge for biomedicine. Science 1977;196:129–136.
6.
Novack DH, Cameron O, Epel E, Ader R, Waldstein SR, Levenstein S, Antoni MH, Wainer AR: Psychosomatic medicine: the scientific foundation of the biopsychosocial model. Acad Psychiatry 2007;31:388–401.
7.
Fava GA, Sonino N: The biopsychosocial model thirty years later. Psychother Psychosom 2008;77:1–2.
8.
Fava GA, Sonino N: The clinical domains of psychosomatics medicine. J Clin Psychiatry 2005;66:849–858.
9.
McEwen BS: Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87:873–904.
10.
Rozanski A, Blumenthal JA, Kaplan J: Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99:2192–2217.
11.
Sonino N, Tomba E, Fava GA: Psychosocial approach to endocrine disease. Adv Psychosom Med 2007;28:21–33.
12.
Wright RJ, Rodriguez M, Cohen S: Review of psychosocial stress and asthma. Thorax 1998;53:1066–1074.
13.
Faravelli C, Catena M, Scarpato A, Ricca V: Epidemiology of life events. Psychother Psychosom 2007;76:361–368.
14.
Engel GL: Psychological aspects of gastrointestinal disorders; in Reiser MF (ed): American Handbook of Psychiatry. New York, Basic Books, 1975, vol 4, pp 653–692.
15.
Rosendal M, Olesen F, Fink P: Management of medically unexplained symptoms. BMJ 2005;30:4–5.
16.
Conti S, Savron G, Bartolucci G, Grandi S, Magelli C, Semprini F, Saviotti FM, Trombini G, Fava GA, Magnani B: Cardiac neurosis and psychopathology. Psychother Psychosom 1989;52:88–91.
17.
Kannel WB, Dawber TR, Cohen ME: The electrocardiogram in neurocirculatory asthenia (anxiety neurosis or neuroasthenia). Ann Intern Med 1958;49:1351–1360.
18.
Lipowski ZJ: Psychosomatic medicine: past and present. 2. Current state. Can J Psychiatry 1986;31:8–13.
19.
Fava GA, Kellner R: Prodromal symptoms in affective disorders. Am J Psychiatry 1991;148:823–830.
20.
Fava GA, Kellner R: Staging. A neglected dimension in psychiatric classifications. Acta Psychiatr Scand 1993;87:225–230.
21.
Paykel ES: The clinical interview for depression. J Affect Disord 1985;9:85–96.
22.
Kellner R: A symptom questionnaire. J Clin Psychiatry 1987;48:269–274.
23.
Sirri L, Grandi S, Fava GA: The illness attitude scales. Psychother Psychosom 2008;77:337–350.
24.
Fava GA, Magelli C, Savron G, Conti S, Bartolucci G, Grandi S, Semprini F, Saviotti FM, Belluardo P, Magnani B: Neurocirculatory asthenia: a reassessment using modern psychosomatic criteria. Acta Psychiatr Scand 1994;89:314–319.
25.
Robins E, Guze SB: Classification of affective disorders: the primary-secondary, the endogenous-reactive, and the neurotic-psychotic concepts; in Williams TA, Katz MM, Shield JA (eds): Recent Advances in the Psychobiology of the Depressive Illness. Washington, Government Printing Office, 1972, pp 283–293.
26.
Fava GA, Grandi S: Differential diagnosis of hypochondriacal fears and beliefs. Psychother Psychosom 1991;55:114–119.
27.
Sonino N, Fava GA, Boscaro M, Fallo F: Life events and neurocirculatory asthenia. J Intern Med 1998;244:523–528.
28.
Paykel ES: The interview for recent life events. Psychol Med 1997;27:301–310.
29.
Fava GA: The concept of psychosomatic disorder. Psychother Psychosom 1992;58:1–12.
30.
Engel GL: The concept of psychosomatic disorder. J Psychosom Res 1967;11:3–9.
31.
Kissen DM: The significance of syndrome shift and late syndrome association in psychosomatic medicine. J Nerv Ment Dis 1963;136:34–42.
32.
Tinetti ME, Fried T: The end of the disease era. Am J Med 2004;116:179–185.
33.
Tinetti ME, Bogardus ST, Agostini JV: Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004;351:2870–2874.
34.
Fava GA, Ruini C, Rafanelli C: Psychometric theory is an obstacle to the progress of clinical research. Psychother Psychosom 2004;73:145–148.
35.
Bech P: Modern psychometrics in clinimetrics. Psychother Psychosom 2004;73:134–138.
36.
Feinstein AR: Clinimetrics. New Haven, Yale University Press, 1987.
37.
Emmelkamp PMG: The additional value of clinimetrics needs to be established rather than assumed. Psychother Psychosom 2004;73:142–144.
38.
Fava GA, Tomba E, Grandi S: The road to recovery from depression. Psychother Psychosom 2007;76:260–265.
39.
Benazzi F: Is there continuity between bipolar and depressive disorders? Psychother Psychosom 2007;76:70–76.
40.
Stangier U, Ukrow U, Schermelleh-Engel K, Grabe M, Lauterbach W: Intrapersonal conflict in goals and values in patients with unipolar depression. Psychother Psychosom 2007;76:162–170.
41.
Hetrick SE, Parker AG, Hickie IB, Purcell R, Yung AR, McGorry PD: Early identification and intervention in depressive disorders: towards a clinical staging model. Psychother Psychosom 2008;77:263–270.
42.
Fava GA, Rafanelli C, Tossani E, Grandi S: Agoraphobia is a disease. Psychother Psychosom 2008;77:133–138.
43.
Dobkin PL, Filipski M, Looper K, Schieir O, Baron M: Identifying target areas of treatment for depressed early inflammatory arthritis patients. Psychother Psychosom 2008;77:298–305.
44.
Van HL, Dekker J, Peen J, van Aalst G, Schoevers RA: Identifying patients at risk of complete non-response in the outpatient treatment of depression. Psychother Psychosom 2008;77:358–364.
45.
Lipkin M, Quill TE, Napodano RJ: The medical interview. Ann Intern Med 1984;100:277–284.
46.
Hampton JR, Harrison MJG, Mitchell JRA, Prichard JS, Seymour C: Relative contributions of history-taking, physical examination, and laboratory investigation to diagnosis and management of medical outpatients. BMJ 1975;2:486–489.
47.
Goldberg RJ, Novack DH: The psychosocial review of systems. Soc Sci Med 1992;35:261–269.
48.
Porcelli P, Sonino N (eds): Psychological Factors Affecting Medical Conditions. A New Classification for DSM-V. Basel, Karger, 2007.
49.
Fava GA, Fabbri S, Sirri L, Wise TN: Psychological factors affecting medical condition: a new proposal for DSM-V. Psychosomatics 2007;48:103–111.
50.
Fava GA, Wise TN: Psychological factors affecting either identified or feared medical conditions: a solution for somatoform disorders. Am J Psychiatry 2007;164:1002–1003.
51.
Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, Rahman A: No health without mental health. Lancet 2007;370:859–877.
52.
Leplège A, Hunt S: The problem of quality of life in medicine. JAMA 1997;278:47–50.
53.
Sonino N, Peruzzi P: A psychoneuroendocrinology service. Psychother Psychosom 2009;78:346–351.
54.
Feinstein AR: An analysis of diagnostic reasoning. 1. The domains and disorders of clinical macrobiology. Yale J Biol Med 1973;46:212–232.
55.
Feinstein AR: An analysis of diagnostic reasoning. 2. The strategy of intermediate decisions. Yale J Biol Med 1973;46:264–283.
56.
Lipowski ZJ: Physical illness and psychopathology. Int J Psychiatry Med 1974;5:483–497.
57.
Kellner R: Psychosomatic syndromes, somatization and somatoform disorders. Psychother Psychosom 1994;61:4–24.
58.
Aaron LA, Buchwald D: A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001;134(9 Pt 2, suppl):868–881.
59.
Fava GA, Grandi S, Rafanelli C, Fabbri S, Cazzaro M: Exploratory therapy of hypochondriasis. J Clin Psychiatry 2000;61:317–322.
60.
Fava GA: Well-being therapy. Psychother Psychosom 1999;68:171–178.
61.
Sonino N, Fava GA: Psychosocial aspects of endocrine disease. Clin Endocrinol 1998;49:1–7.
62.
Sonino N, Fava GA: Rehabilitation in endocrine patients. A novel psychosomatic approach. Psychother Psychosom 2007;76:319–324.
63.
Balercia G, Boscaro M, Lombardo F, Carosa E, Lenzi A, Jannini EA: Sexual symptoms in endocrine diseases. Psychother Psychosom 2007;76:134–140.
64.
Feinstein AR: Basic biomedical science and the destruction of the pathophysiological bridge from bench to bedside. Am J Med 1999;107:461–467.
65.
Fava GA, Freyberger HJ, Bech P, Christodoulou G, Sensky T, Theorell T, Wise TN: Diagnostic criteria for use in psychosomatic research. Psychother Psychosom 1995;63:1–8.
66.
Engel GL: Conversion symptoms; in Mac Bryde CM, Blacklow RS (eds): Signs and Symptoms. Philadelphia, Lippincott, 1970, pp 650–699.
67.
Goldbeck R: Denial in physical illness. J Psychosom Res 1997;43:575–593.
68.
de Figuereido JM: Demoralization and psychotherapy. Psychother Psychosom 2007;76:129–133.
69.
Mangelli L, Fava GA, Grandi S, Grassi L, Ottolini F, Porcelli P, Rafanelli C, Rigatelli M, Sonino N: Assessing demoralization and depression in the setting of medical disease. J Clin Psychiatry 2005;66:391–394.
70.
Mangelli L, Fava GA, Grassi L, Ottolini F, Paolini S, Porcelli P, Rafanelli C, Rigatelli M, Sonino N: Irritable mood in Italian patients with medical disease. J Nerv Ment Dis 2006;194:226–228.
71.
Härter M, Baumeister H, Reuter K, Jacobi F, Höfler M, Bengel J, Wittchen HU: Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychother Psychosom 2007;76:354–360.
72.
McKegney PF: The incidence and characteristics of patients with conversion reactions. Am J Psychiatry 1967;124:542–545.
73.
Orchard WH: Anxiety in patients with coronary disease. Aust N Z J Psychiatry 1969;3:316–320.
74.
Lishman WA: Organic Psychiatry, ed 3. Oxford, Blackwell, 1998, pp 384–385.
75.
Fava GA, Morphy MA, Sonino N: Affective prodromes of medical illness. Psychother Psychosom 1994;62:141–144.
76.
Mangelli L, Bravi A, Fava GA, Ottolini F, Porcelli P, Rafanelli C, Rigatelli M, Sonino N: Assessing somatization with various diagnostic criteria. Psychosomatics 2009;50:38–41.
77.
Beresnevaité M, Taylor GJ, Bagby RM: Assessing alexithymia and type A behavior in coronary heart disease patients. Psychother Psychosom 2007;76:186–192.
78.
Ferrari S, Galeazzi GM, Mackinnon A, Rigatelli M: Frequent attenders in primary care. Psychother Psychosom 2008;77:306–314.
79.
Ryff CD, Dienberg Love G, Urry HL, Muller D, Rosenkranz MA, Friedman EM, Davidson RJ, Singer B: Psychological well-being and ill-being. Psychother Psychosom 2006;75:85–95.
80.
Schubert C: Psychological well-being and ill-being and their biological correlates. Psychother Psychosom 2007;76:252–253.
81.
Dantzer R: Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology 2005;30:947–952.
82.
Price DD, Finniss DG, Benedetti F: A comprehensive review of the placebo effect. Annu Rev Psychol 2008;59:565–590.
83.
Walach H, Bosch H, Lewith G, Naumann J, Schwarzer B, Falk S, Kohls N, Haraldsson E, Wiesendanger H, Nordmann A, Tomasson H, Prescott P, Bucher HC: Effectiveness of distant healing for patients with chronic fatigue syndrome. Psychother Psychosom 2008;77:158–166.
84.
Thayer JF, Brosschot JF: Psychosomatics and psychopathology. Psychoneuroendocrinology 2005;30:1050–1058.
85.
Zachariae R, Paulsen K, Mehlsen M, Jensen AB, Johansson A, von der Maase H: Chemotherapy-induced nausea, vomiting and fatigue. Psychother Psychosom 2007;76:376–384.
86.
Carroll BJ: Brain mechanisms in manic depression. Clin Chem 1994;40:303–308.
87.
Fava GA: Irritable mood and physical illness. Stress Med 1987;3:293–299.
88.
Abbate-Daga G, Fassino S, Lo Giudice R, Rainero I, Gramaglia C, Marech L, Amianto F, Gentile S, Pinessi L: Anger, depression and personality dimensions in patients with migraine without aura. Psychother Psychosom 2007;76:122–128.
89.
Kamarck TW, Haskett RF, Muldoon M, Flory JD, Anderson B, Bies R, Pollock B, Manuck SB: Citalopram intervention for hostility. J Consult Clin Psychol 2009;77:174–188.
90.
World Health Organization: World Health Organization Constitution. Geneva, World Health Organization, 1948, p 28.
91.
Ryff CD, Singer B: Psychological well-being. Psychother Psychosom 1996;65:14–23.
92.
Fava GA, Tomba E: Increasing psychological well-being and resilience by psychotherapeutic methods. J Pers, in press.
93.
Pressman SD, Cohen S: Does positive affect influence health? Psychol Bull 2005;131:925–971.
94.
Chida Y, Steptoe A: Positive psychological well-being and mortality. Psychosom Med 2008;70:741–756.
95.
Charney DS: Psychobiological mechanisms of resilience and vulnerability. Am J Psychiatry 2004;161:195–216.
96.
Cloninger CR: Systematic method for clinical description and classification of personality. Arch Gen Psychiatry 1987;44:573–588.
97.
Tabibnia G, Zaidel E: Alexithymia, interhemispheric transfer, and right hemispheric specialization. Psychother Psychosom 2005;75:81–92.
98.
Romei V, De Gennaro L, Fratello F, Curcio G, Ferrara M, Pascual-Leone A, Bertini M: Interhemispheric transfer deficit in alexithymia. Psychother Psychosom 2008;77:175–181.
99.
Galderisi S, Mancuso F, Mucci A, Garramone S, Zamboli R, Maj M: Alexithymia and cognitive dysfunction in patients with panic disorder. Psychother Psychosom 2008;77:182–188.
100.
Fava M, Littman A, Halperin P: Neuroendocrine correlates of the type A behavior pattern. Int J Psychiatry Med 1987;17:289–307.
101.
Engel GL: How much longer must medicine’s science be bound by a seventeenth century world view? Psychother Psychosom 1992;57:3–16.
102.
Dafoe W, Husten P: Current trends in cardiac rehabilitation. CMAJ 1997;156:527–532.
103.
Nieuwenhuijsen ER, Zemper E, Miner KR, Epstein M: Health behavior change models and theories. Disabil Rehabil 2006;28:245–256.
104.
Joosten EA, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CP, de Jong CA: Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 2008;77:219–226.
105.
Bodenheimer T, Lorig K, Holman H, Grumbach K: Patient self-management of chronic disease in primary care. JAMA 2002;288:2469–2475.
106.
Jones DS: Textbook of Functional Medicine. Gig Harbor, Institute for Functional Medicine, 2005.
107.
Lolak S, Connors GL, Sheridan MJ, Wise TN: Effects of progressive muscle relaxation training on anxiety and depression in patients enrolled in an outpatients pulmonary rehabilitation program. Psychother Psychosom 2008;77:119–125.
108.
Korstjens I, May AM, von Woert E, Mesters I, Tan F, Ros WJ, Hoekstra-Weebers JE, van der Schans CP, van den Borne B: Quality of life after self-management cancer rehabilitation. Psychosom Med 2008;70:422–429.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
